| Malaysian cosmetic market: Current and future prospects MA Hassali, SK Al-Tamimi, OT Dawood, AK Verma, F Saleem Pharmaceutical Regulatory Affairs 4 (4), 1-3, 2015 | 107 | 2015 |
| Antibiotic abuse in developing countries R Abdulah Pharm Regul Aff 1 (2), 1000e106, 2012 | 65 | 2012 |
| Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental L Tomljenovic, CA Shaw Pharmaceut Reg Affairs S 12, 2, 2012 | 39 | 2012 |
| Micellar solubilization in the formulation development of poorly soluble naproxen PD Maheswari, D Rambhau, ML Narasu Pharm Reg Affairs 2 (108), 2, 2013 | 21 | 2013 |
| The three-level approach: a framework for ensuring medicines quality in limited-resource countries VS Pribluda, A Barojas, V Coignez, S Bradby, Y Dijiba, L El-Hadri, ... Pharmaceut Reg Affairs 3 (1), 117, 2014 | 20 | 2014 |
| Biosimilars: an emerging market opportunities in India P Rushvi, K Charmy, C Nirav, C Narendra Pharmaceut Reg Affairs 5 (1), 1-7, 2016 | 17 | 2016 |
| Harmonized guideline on limit and testing of elemental impurities in pharmaceutical substances: a review MM Reddy, KH Reddy, MU Reddy Pharmaceut Reg Affairs 5 (2), 1-8, 2016 | 17 | 2016 |
| Pharma regulations for generic drug products in India and US: case studies and future prospectives S Swain, A Dey, CN Patra, ME Bhanoji Rao Pharmaceut Reg Affairs 3 (119), 1-6, 2014 | 16 | 2014 |
| FDA regulation of medical devices and medical device reporting N Teow, SJ Siegel Pharmaceut Reg Affairs 2 (110), 2, 2013 | 14 | 2013 |
| The use of medicinal plants in human healthcare: a scoop on safety M Eddouks, D Ghanimi Pharm Regul Aff 3 (1), 1-21, 2013 | 14 | 2013 |
| Marijuana toxicity: heavy metal exposure through state-sponsored access to “la Fee Verte” DV Gauvin, ZJ Zimmermann, J Yoder, R Tapp Pharm. Regul. Aff. Open Access 7, 1-10, 2018 | 13 | 2018 |
| Impact of API (active pharmaceutical ingredient) source selection on generic drug products UR Mallu, AK Nair, J Sankar, HR Bapatu, MP Kumar, S Narla, TA Bhanap, ... Pharmaceut Reg Affairs 4 (2), 11, 2015 | 13 | 2015 |
| Drug review differences across the United States and the European Union MM Sifuentes, A Giuffrida Pharmaceut Reg Affairs 4, e156, 2015 | 13 | 2015 |
| Patient Compliance: An Untold Story or a Fairy Tale AK Mohiuddin Pharmaceut Reg Affairs 7 (2), 207, 2018 | 9 | 2018 |
| Regulatory requirements and drug approval process in India, Europe and US AM Sawant, DP Mali, DA Bhagwat Pharmaceut Reg Affairs 7 (210), 2, 2018 | 8 | 2018 |
| Health and beauty cosmeceuticals industry and market expansion in Saudi Arabia E Tambo, H Almeer, Y Alshamrani Pharmaceut Reg Affairs 5 (172), 2, 2016 | 8 | 2016 |
| Pharmaceutical good manufacturing practice regulatory affairs in Sudan: continuous debate between regulatory authority and manufacturers A Abedellah, M Noordin, AA Zaki Pharmaceut. Reg. Affairs 5 (166), 2, 2016 | 8 | 2016 |
| Current regulatory scenario for conducting clinical trials in India B Ramu, M Sathish Kumar, M Ramakrishna Pharmaceut Reg Affairs 4 (2), 1-3, 2015 | 8 | 2015 |
| Impact of pharmacovigilance in healthcare system: regulatory perspective S Swain, CN Patra Pharmaceut Reg Affairs 3 (5), 2014 | 8 | 2014 |
| Non-equivalence of antibiotic generic drugs and risk for intensive care patients C Kirkpatrick, R Ramzan, R Mykhaylo, B Mike, G Shahram Pharmaceut Reg Affairs 2 (1), 1-7, 2013 | 8 | 2013 |
